Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 5/2010

01-09-2010

Quality of Life in Multiple Sclerosis: Determinants, Measurement, and Use in Clinical Practice

Authors: Deborah M. Miller, Rebecca Allen

Published in: Current Neurology and Neuroscience Reports | Issue 5/2010

Login to get access

Abstract

Multiple sclerosis (MS) is a complex demyelinating disease with a relatively unpredictable course. It is well established that MS has a significant impact on health-related quality of life (HRQL) for individuals at all stages of the disease. It is argued that clinicians offer treatment to their patients for three reasons: 1) to increase longevity, 2) to prevent future morbidity, and 3) to make patients feel better. To assess how well they are accomplishing the third of these goals, clinicians have come to depend on the direct measurement of patients’ HRQL. We review the many physical and emotional symptoms and other consequences of MS that negatively influence HRQL, how HRQL is measured, the unique information these measures provide compared with clinical parameters, the benefit of treatment interventions, and how to include HRQL assessment and data from other sources in clinical encounters and suggest measures to consider for clinical use.
Literature
1.
Stuke K, Flachenecker P, Zettl UK, et al.: Symptomatology of MS: results from the German MS Registry. J Neurol 2009, 256(11):1932–1935.CrossRefPubMed
2.
Benito-Leon J, Morales JM, Rivera-Navarro J, Mitchell A: A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 2003, 25(23):1291–1303.CrossRefPubMed
3.
Foley JF, DW Brandes: Redefining functionality and treatment efficacy in multiple sclerosis. Neurology 2009, 72(23 Suppl 5):S1–S11.CrossRefPubMed
4.
Ware JE Jr, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey: Users Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
5.
Hobart J, Lamping D, Fitzpatrick R, et al.: The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001, 124:962–973.CrossRefPubMed
6.
Kattan MW: Comparing treatment outcomes using utility assessment for health-related quality of life. Oncology 2003, 17(12):1687–1693; discussion 1693–1694, 1697, 1701.
7.
Rudick RA, Miller DM, Clough JD, et al.: Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992, 49(12):1237–1242.
8.
Chopra P, Herrman H, Kennedy G: Comparison of disability and quality of life measures in patients with long-term psychotic disorders and patients with multiple sclerosis: an application of the WHO Disability Assessment Schedule II and WHO Quality of Life-BREF. Int J Rehabil Res 2008, 31(2):141–149.CrossRefPubMed
9.
Pittock SJ, Mayr WT, McClelland RL, et al.: Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. Arch Neurol 2004, 61(5):679–686.CrossRefPubMed
10.
• Treadaway K, Cutter G, Salter A, et al.: Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009, 256(4):568–576. This study characterizes factors associated with the failure to fully adhere to disease-modifying injection therapy for MS and underscores the principles associated with optimizing adherence and its implications for effective treatment of the disease process in MS.
11.
Mowry EM, Beheshtian A, Waubant E, et al.: Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009, 72(20):1760–1765.CrossRefPubMed
12.
Wynia K, Middel B, de Ruiter H, et al.: Stability and relative validity of the Multiple Sclerosis Impact Profile (MSIP). Disabil Rehabil 2008, 30(14):1027–1038.CrossRefPubMed
13.
• Kern S, Schrempf W, Schneider H, et al.: Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. Mult Scler 2009, 15(6):752–758. Patients with early-stage MS differ significantly in their psychological distress compared with healthy controls. Psychological distress in these patients is associated with neurologic disability, but it also is present in patients with minimal to no neurologic disability. This study identified psychological distress as an independent predictor for MS-related QoL.
14.
Nortvedt MW, Riise T: The use of quality of life measures in multiple sclerosis research. Mult Scler 2003, 9(1):63–72.CrossRefPubMed
15.
Beiske AG, Naess H, Aarseth JH, et al.: Health-related quality of life in secondary progressive multiple sclerosis. Mult Scler 2007, 13(3):386–392.CrossRefPubMed
16.
Mowry EM, Loguidice MJ, Daniels AB, et al.: Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry 2009, 80(7):767–772.CrossRefPubMed
17.
Mitchell A, Kemp S, Benito-Leon J, Ruber M: The influence of cognitive impairment on health-related quality of life in neurological disease. Acta Neuropsychiatrica 2010, 22:2–13.CrossRef
18.
Phillips LH, Saldias A, McCarrey A, et al. Attentional lapses, emotional regulation and quality of life in multiple sclerosis. Br J Clin Psychol 2009, 48(Pt 1):101–106.CrossRefPubMed
19.
Merlino G, Fratticci L, Lenchig C, et al.: Prevalence of 'poor sleep' among patients with multiple sclerosis: an independent predictor of mental and physical status. Sleep Med 2009, 10(1):26–34.CrossRefPubMed
20.
Svendsen KB, Jensen TS, Hansen HJ, Bach FW: Sensory function and quality of life in patients with multiple sclerosis and pain. Pain 2005, 114(3):473–481.CrossRefPubMed
21.
Nortvedt MW, Riise T, Frugard J, et al.: Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007, 13(1):106–112.CrossRefPubMed
22.
Goverover Y, Chiaravalloti N, Gaudino-Goering E, et al.: The relationship among performance of instrumental activities of daily living, self-report of quality of life, and self-awareness of functional status in individuals with multiple sclerosis. Rehabil Psychol 2009, 54(1):60–68.CrossRefPubMed
23.
Goretti B, Portaccio E, Zipoli V, et al.: Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. Neurol Sci 2009, 30(1):15–20.CrossRefPubMed
24.
Brenk A, Laun K, Haase CG: Short-term cognitive training improves mental efficiency and mood in patients with multiple sclerosis. Eur Neurol 2008, 60(6):304–309.CrossRefPubMed
25.
Motl RW, McAuley E, Snook EM, Gliottoni RC: Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. Psychol Health Med 2009, 14(1):111–124.CrossRefPubMed
26.
McCullagh R, Fitzgerald AP, Murphy RP, Cooke G: Long-term benefits of exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study. Clin Rehabil 2008, 22(3):206–214.CrossRefPubMed
27.
Lily O, McFadden E, Hensor E, et al.: Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler 2006, 12(6):808–813.CrossRefPubMed
28.
Zivadinov R, Zorzon M, Tommasi MA, et al.: A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003, 216(1):113–118.CrossRefPubMed
29.
Hopman WM, Coo H, Pavlov A, et al.: Multiple sclerosis: change in health-related quality of life over two years. Can J Neurol Sci 2009, 36(5):554–561.PubMed
30.
Putzki N, Fischer J, Gottwald K, et al.: Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol 2009, 16(6):713–720.CrossRefPubMed
31.
Ziemssen T: Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009, 277(Suppl 1):S37–S41.CrossRefPubMed
32.
Hadjimichael O, Vollmer T, Oleen-Burkey M; North American Research Committee on Multiple Sclerosis: Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008, 6:100.CrossRefPubMed
33.
Rudick RA, Miller D, Hass S, et al.: Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007, 62(4):335–346.CrossRefPubMed
34.
Guyatt GH, Ferrans CE, Halyard MY, et al.: Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clin Proc 2007, 82(10):1229–1239 [Published erratum appears in Mayo Clin Proc 2007, 82(12):1579].
35.
Institute of Medicine, Committee on the Quality of Health Care in America: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington DC: National Academy Press; 2001.
36.
Epping-Jordan JE, Pruitt SD, Bengoa R, Wagner EH. Improving the quality of health care for chronic conditions. Qual Saf Health Care 2004, 13(4):299–305.CrossRefPubMed
37.
Wagner EH, Bennett SM, Austin BT, et al.: Finding common ground: patient-centeredness and evidence-based chronic illness care. J Altern Complement Med 2005, 11(Suppl 1):S7–S15.PubMed
38.
Guyatt G, Jaeschke R, Feeny DH, et al.: Measurements in clinical trials: choosing the right approach. In Quality of Life and Pharmacoeconomics in Clinical Trials. Edited by Spilker B. Philadelphia: Lippincott-Raven; 1996.
39.
Guarnaccia JB, Aslan M, O'Connor TZ, et al.: Quality of life for veterans with multiple sclerosis on disease-modifying agents: relationship to disability. J Rehabil Res Dev 2006, 43(1):35–44.CrossRefPubMed
40.
•• Frost MH, Bonomi AE, Cappelleri JC, et al.: Applying quality-of-life data formally and systematically into clinical practice. Mayo Clin Proc 2007, 82(10):1214–1228. The authors discuss the use of QoL data in patient care and review approaches used to integrate QoL assessment into the clinical setting. They highlight select QoL measures that have been applied successfully in the clinical setting. These measures have been shown to identify key QoL issues, improve patient–clinician communication, and improve and enhance patient care. However, the work done to date requires continued development. Continued research is needed to provide information about benefits and address limitations of current approaches.
41.
Confavreux C, Paty DW: Current status of computerization of multiple sclerosis clinical data for research in Europe and North America: the EDMUS/MS-COSTAR connection. European Database for Multiple Sclerosis. Multiple Sclerosis-Computed Stored Ambulatory Record. Neurology 1995, 45(3 Pt 1):573–576.
42.
Koch-Henriksen N, Rasmussen S, Stenager E, Madsen M: The Danish Multiple Sclerosis Registry. History, data collection and validity. Dan Med Bull 2001, 48(2):91–94.PubMed
43.
44.
Minden SL, Frankel D, Hadden L, et al.: The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006, 12(1):24–38.CrossRefPubMed
45.
Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34(3):220–233.CrossRefPubMed
46.
Khan F, Turner-Stokes L, Ng L, Kilpatrick T: Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev 2007, CD006036.
47.
Motl RW, Gosney JL: Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. Mult Scler 2008, 14(1):129–135.CrossRefPubMed
48.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121–1123.PubMed
49.
Nowinski CJ, Victorson DE, Miller DM, et al.: Clinician attitudes toward Quality of Life measures for neurological disorders. Neurology 2006, 66(Suppl 2):A325 (P04.145).
50.
Brozek JL, Guyatt GH, Schunemann HJ: How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes 2006, 4:69.CrossRefPubMed
51.
Greenhalgh J, Long AF, Flynn R: The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory? Soc Sci Med 2005, 60(4):833–843.CrossRefPubMed
52.
Valderas JM, Kotzeva A, Espallargues M, et al.: The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res 2008, 17(2):179–193.CrossRefPubMed
53.
54.
55.
Fischer JS, LaRocca NG, Miller DM, et al.: Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999, 5(4):251–259.PubMed
56.
Vickrey BG, Hays RD, Harooni R, et al.: A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995, 4(3):187–206.CrossRefPubMed
57.
Heiskanen S, Merilainen P, Pietila A-M: Health-related quality of life—testing the reliability of the MSQOL-54 instrument among MS patients. Scand J Caring Sci 2007, 21:199–206 [published erratum appears in Scand J Caring Sci 2007, 21:290].
58.
Cella DF, Dineen K, Arnason B, et al.: Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996, 47(1):129–139.PubMed
59.
Ford HL, Gerry E, Tennant A, et al.: Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001, 15:247–258.CrossRefPubMed
60.
Lankhorst GJ, Jelles F, Smits RC, et al.: Quality of life in multiple sclerosis: the disability and impact profile (DIP). J Neurol 1996, 243(6):469–474.CrossRefPubMed
61.
Schwartz CE, Coulthard-Morris L, Zeng Q, Retzlaff P: Measuring self-efficacy in people with multiple sclerosis: a validation study. Arch Phys Med Rehabil 1996, 77(4):394–398.CrossRefPubMed
62.
Ferrans CE, Powers MJ: Quality of life index: development and psychometric properties. Adv Nurs Sci 1985, 8(1):15–24.
63.
Simeoni M, Auquier P, Fernandez O, et al.: Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler 2008, 14(2):219–230.CrossRefPubMed
64.
Gold SM, Heesen C, Schulz H, et al.: Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler 2001, 7(2):119–130.PubMed
65.
Ramp M, Khan F, Misajon RA, Pallant JF: Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29. Health Qual Life Outcomes 2009, 7:58.CrossRefPubMed
66.
Rotstein Z, Barak Y, Noy S, Achiron A: Quality of life in multiple sclerosis: development and validation of the 'RAYS' scale and comparison with the SF-36. Int J Qual Health Care 2000, 12:511–517.CrossRefPubMed
67.
Doward LC, McKenna SP, Meads DM, et al.: The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler 2009, 15(9):1092–1102.CrossRefPubMed
68.
Wesson JM, Cooper JA, Jehle LS, et al.: The functional index for living with multiple sclerosis: development and validation of a new quality of life questionnaire. Mult Scler 2009, 15(10):1239–1249.CrossRefPubMed
Metadata
Title
Quality of Life in Multiple Sclerosis: Determinants, Measurement, and Use in Clinical Practice
Authors
Deborah M. Miller
Rebecca Allen
Publication date
01-09-2010
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 5/2010
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-010-0132-4

Other articles of this Issue 5/2010

Current Neurology and Neuroscience Reports 5/2010 Go to the issue

Clinical Trial Report

Tarenflurbil in Patients with Mild Alzheimer’s Disease

ReviewPaper

Emerging Oral Therapies in Multiple Sclerosis

Clinical Trial Report

Oral Disease-Modifying Therapies for Multiple Sclerosis: Are We There Yet?

ReviewPaper

Consent in Impaired Populations

ReviewPaper

Hormonal Influences on Cognition and Risk for Alzheimer’s Disease

ReviewPaper

Minding the Aging Brain: Technology-Enabled Cognitive Training for Healthy Elders